-
Mashup Score: 14Advances in Cancer Immunotherapy: A Focus on Genitourinary Cancers - 2 month(s) ago
Join SITC and a panel of experts for an afternoon of in-depth education on all aspects of clinical implementation of immunotherapy for genitourinary cancers.
Source: www.sitcancer.orgCategories: General Medicine News, Partners & KOLsTweet
-
Mashup Score: 13Advances in Cancer Immunotherapy: A Focus on Genitourinary Cancers - 2 month(s) ago
Join SITC and a panel of experts for an afternoon of in-depth education on all aspects of clinical implementation of immunotherapy for genitourinary cancers.
Source: www.sitcancer.orgCategories: General Medicine News, Partners & KOLsTweet-
Advance your education with the latest updates presented at @sitcancer’s Advances in Cancer Immunotherapy: A Focus on Genitourinary Cancers program June 11. Improve patient outcomes and earn CME, CNE, CPE or MOC credits. Register: https://t.co/tdMj7lExB1
-
-
Mashup Score: 13Advances in Cancer Immunotherapy: A Focus on Genitourinary Cancers - 3 month(s) ago
Join SITC and a panel of experts for an afternoon of in-depth education on all aspects of clinical implementation of immunotherapy for genitourinary cancers.
Source: www.sitcancer.orgCategories: General Medicine News, Partners & KOLsTweet-
Advance your education with the latest updates presented at @sitcancer’s Advances in Cancer Immunotherapy: A Focus on Genitourinary Cancers program June 11. Improve patient outcomes and earn CME, CNE, CPE or MOC credits. Register: https://t.co/tdMj7lExB1
-
-
Mashup Score: 50GU Tumor Board®: Real World Strategies to Inform Individualized Care in Renal Cell Carcinoma - 4 month(s) ago
January 25, 2024
Source: www.gotoper.comCategories: General Medicine News, Partners & KOLsTweet-
Can’t wait for GU ASCO!! Join us for the GU tumor board in RCC. Jan 25 from 7-9 pm! @tompowles1 @DrChoueiri @AlbigesL https://t.co/UXzaTFQT6p
-
-
Mashup Score: 0KCRS23: More Time to Make Your Mark - 1 year(s) ago
We’ve got really good news for you! KCRS23 Call for Abstracts: Deadline Extended! Dear Kidney Cancer Research Community, We are excited to see the many high-quality abstracts we have received s
Source: KidneyCANCategories: Hem/Oncs, Latest HeadlinesTweet-
The KCRS meeting abstract deadline deadline has been extended!! Will be a fabulous meeting focused on translational science, biomarkers, and novel therapeutics! @KidneyCancer @kcCURE https://t.co/NWhWqFGcJE
-
-
Mashup Score: 7
The Oncologic Drugs Advisory Committee has discussed the approval application for olaparib plus abiraterone and prednisone or prednisolone for patients with metastatic castration-resistant prostate cancer and voted on its potential future.
Source: Targeted OncologyCategories: Hem/Oncs, Latest HeadlinesTweet-
There you have it. ODAC votes yes on restricted label for olaparib and abiraterone for men with 1L mCRPC. @ASCO @FDAOncology @OncoAlert https://t.co/VIUAZ5ecje
-
-
Mashup Score: 2
Enfortumab vedotin plus pembrolizumab is now an FDA approved treatment based on positive phase 1b/2 findings.
Source: Targeted OncologyCategories: Hem/Oncs, Latest HeadlinesTweet-
FDA Approves Enfortumab Vedotin/Pembrolizumab Combo for Advanced Urothelial Cancer https://t.co/1vN0dmRiNa via @targetedonc
-
Exciting to see the combination of Pembrolizumab + Enfortumab approved for frontline UC patients ineligible for cisplatin. Very encouraging efficacy from EV-103. EV-302 currently investigating in phase 3. @urotoday @ALLIANCE_org https://t.co/5PcLaublU9
-
-
Mashup Score: 4Patricia M. LoRusso, DO, PhD (hc) - 1 year(s) ago
Dr. LoRusso is a candidate for President-Elect of the AACR.
Categories: Hem/Oncs, Latest HeadlinesTweet-
Amazing to see Dr. Pat LoRusso elected as the future president of AACR!! She is a tremendous researcher, scientist, and patient advocate! @UCSanDiego @AACR @AACRPres https://t.co/nV7o267ecP
-
-
Mashup Score: 1
Trends in Prostate Cancer Mortality in the United States of America, WONDER Database, prostate cancer, prostate specific antigen (PSA), prostate cancer mortality rates, PSA screening, prostate cancer mortality rates by race and geography.
Source: www.urotoday.comCategories: Hem/Oncs, Latest HeadlinesTweet-
Excellent work by Chinmay Jani highlighting trends in prostate cancer mortality. While mortality has improved, decline was not uniform across states and racial groups. Need to bridge disparities gap. @UCSanDiego @urotoday https://t.co/OltbgQhDwX
-
-
Mashup Score: 2Kidney Cancer Clinical Trial: The RadiCaL Study - 1 year(s) ago
This phase II trial studies whether adding radium-223 dichloride to the usual treatment, cabozantinib, improves outcomes in patients with renal cell cancer that…
Source: VimeoCategories: Hem/Oncs, Latest HeadlinesTweet-
The Radical trial is currently accruing patients. Study for patients with RCC with bone mets looking at radium-223 + Cabo. Check out our patient video. @ALLIANCE_org @kidneycan @KidneyCancer @UCSDCancer @DrChoueiri https://t.co/P4g8rsElN3
-
Advance your education with the latest updates presented at @sitcancer’s Advances in Cancer Immunotherapy: A Focus on Genitourinary Cancers program June 11. Improve patient outcomes and earn CME, CNE, CPE or MOC credits. Register: https://t.co/tdMj7lExB1